This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Support & ResourcesSupport & ResourcesVideosMaterials

Click here for Trumenba®▼ (meningococcal group B vaccine (recombinant, adsorbed)) Prescribing Information for Great Britain (GB) and Northern Ireland (NI). Black triangle status is applicable in Great Britain. Adverse event reporting information can be found at the bottom of the page.

Meningococcal group B vaccine

Trumenba (meningococcal group B vaccine (recombinant, adsorbed)) is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.1

Vaccinate with Trumenba to help protect adolescents and young adults from MenB disease.1​​​​​​​

Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants.1 fHbp is found on the surface of meningococcal bacteria and helps bacteria to avoid host immune defences.
fHbp variants segregate into 2 immunologically distinct subfamilies, A and B.1 Over 91%** of MenB strains express sufficient levels of fHbp subfamily A or B to be susceptible to bactericidal killing by Trumenba induced antibodies.

​​​**A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.1.

Trumenba offers two dosing schedules for adolescents and young adults1Dosing Schedules

2-dose schedule1
This includes 2 doses (0.5ml each) administered 6 months apart.

3-dose schedule1
This includes 2 doses (0.5ml each) administered at least 1 months apart, followed by a third dose at least 4 months after the second dose.

Dosing considerations1
  • A booster dose should be considered following either dosing regimen for individuals at continued risk of IMD.
  • The use of this vaccine should be in accordance with official recommendations1
Trumenba can be co-administered concomitantly with​​​​​​​:​​​​​​​
  • Quadrivalent Human Papillomavirus vaccine (HPV4)
  • Meningococcal Serogroups A, C, W, Y conjugate vaccine (MenACWY)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, Acellular Pertussis, and Inactivated Poliovirus Vaccine (TdaP-IPV)
When given concomitantly with other vaccines Trumenba must be administered at a separate injection site.1 Trumenba should not be mixed with other vaccines in the same syringe.​​​​​​​​​​​​​​
Reference:Trumenba. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2670​​​​​​​​​​​​​​
PP-TRU-GBR-0144. May 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​